ERBB2 and breast cancer: According to www.fda.gov, the Food and Drug Administration approved Palbociclib in February 2015 as the first CDK4/6 inhibitor (in combination with Letrozole) for the treatment of HR-positive, HER2-negative advanced breast cancer as an initial endocrine based therapy in postmenopausal women.